Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients With Ovarian Cancer

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, recently announced results of the first-ever low-grade ovarian cancer (LGSOC )Patient Impact Survey that reveal the particular challenges with diagnosis, disease management and mental, physical, and emotional well-being experienced by people living with this rare and difficult to treat disease.

Low-grade serous ovarian cancer (LGSOC) is a rare, highly recurrent ovarian cancer which often affects younger women as compared to the more common high-grade serous ovarian cancer—with a median age at diagnosis between 45 and 55—and is associated with slow but persistent tumor growth and a high mortality rate.This multi-national, online survey conducted by The Harris Poll among patients diagnosed with LGSOC was developed through a global collaboration with patient advocacy groups and medical leaders to better understand and address the urgent challenges faced by this community.

DocWire News spoke with Dr. David Gershenson, expert researcher in rare ovarian cancers and LGSOC Patient Impact Advisory Committee member, about the survey findings and their implications.